Glofitamab effectively bridging CD19-specific CAR T- cell therapy while maintaining safety in patients with refractory DLBCL
Year: 2025
Type: conference-abstract
Source: Blood
Institutions: Tongji University, Nanyang Medical College
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417005238
Cites:
Cited by:
Related to: